

SCI PHARMTECH, INC. AND SUBSIDIARIES**Consolidated Financial Statements****With Independent Auditors' Review Report
For the Three Months Ended March 31, 2024 and 2023**

Address: No.61, LN. 309, HAIHUN.RD., LUZHU DIST., TAOYUAN CITY 33856,
TAIWAN (R.O.C)
Telephone: (03)354-3133

The independent auditors' review report and the accompanying consolidated financial statements are the English translation of the Chinese version prepared and used in the Republic of China. If there is any conflict between, or any difference in the interpretation of the English and Chinese language independent auditors' review report and consolidated financial statements, the Chinese version shall prevail.

Table of contents

Contents	Page
1. Cover Page	1
2. Table of Contents	2
3. Independent Auditors' Review Report	3
4. Consolidated Balance Sheets	4
5. Consolidated Statements of Comprehensive Income	5
6. Consolidated Statements of Changes in Equity	6
7. Consolidated Statements of Cash Flows	7
8. Notes to the Consolidated Financial Statements	
(1) Company history	8
(2) Approval date and procedures of the consolidated financial statements	8
(3) New standards, amendments and interpretations adopted	8~10
(4) Summary of material accounting policies	10~11
(5) Significant accounting assumptions and judgments, and major sources of estimation uncertainty	11
(6) Explanation of significant accounts	12~37
(7) Related-party transactions	37~38
(8) Pledged assets	38
(9) Commitments and contingencies	39
(10) Losses Due to Major Disasters	39
(11) Subsequent Events	39
(12) Other	39~40
(13) Other disclosures	
(a) Information on significant transactions	40~41
(b) Information on investees	41
(c) Information on investment in mainland China	41
(d) Major shareholders	42
(14) Segment information	42



安侯建業聯合會計師事務所
KPMG

台北市110615信義路5段7號68樓(台北101大樓)
68F., TAIPEI 101 TOWER, No. 7, Sec. 5,
Xinyi Road, Taipei City 110615, Taiwan (R.O.C.)

電話 Tel + 886 2 8101 6666
傳真 Fax + 886 2 8101 6667
網址 Web kpmg.com/tw

Independent Auditors' Review Report

To the Board of Directors of SCI Pharmtech, Inc.:

Introduction

We have reviewed the accompanying consolidated balance sheets of SCI Pharmtech, Inc. and its subsidiaries as of March 31, 2024 and 2023, and the related consolidated statements of comprehensive income, changes in equity and cash flows for the three months ended March 31, 2024 and 2023, and notes to the consolidated financial statements, including a summary of significant accounting policies. Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Accounting Standard 34, "Interim Financial Reporting" endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China. Our responsibility is to express a conclusion on the consolidated financial statements based on our reviews.

Scope of Review

Except as explained in the Basis for Qualified Conclusion paragraph, we conducted our reviews in accordance with the Standard on Review Engagements 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" of the Republic of China. A review of the consolidated financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing of the Republic of China and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Basis for Qualified Conclusion

As stated in Note 6(f), the other equity accounted investments of the SCI Pharmtech, Inc. and its subsidiaries in its investee companies of \$140,690 thousand and \$139,320 thousand as of March 31, 2024 and 2023, respectively, and its equity in net earnings (losses) on these investee companies of \$(4,118) thousand and \$(1,997) thousand respectively, were recognized solely on the financial statements prepared by these investee companies, but not reviewed by independent auditors.

Qualified Conclusion

Except for the adjustments, if any, as might have been determined to be necessary had the consolidated financial statements of certain equity accounted investee companies described in the Basis for Qualified Conclusion paragraph above been reviewed by independent auditors, based on our reviews, nothing has come to our attention that causes us to believe that the accompanying consolidated financial statements, do not present fairly, in all material respects, the consolidated financial position of SCI Pharmtech, Inc. and its subsidiaries as of March 31, 2024 and 2023, and of its consolidated financial performance and its consolidated cash flows for the three months ended March 31, 2024 and 2023 in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Accounting Standard 34, “Interim Financial Reporting” endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China.

The engagement partners on the review resulting in this independent auditors’ report are Hsin, Yu-Ting and Huang, Keng-Chia.

KPMG

Taipei, Taiwan (Republic of China)
May 9, 2024

Notes to Readers

The accompanying consolidated financial statements are intended only to present the consolidated financial position, financial performance and cash flows in accordance with the accounting principles and practices generally accepted in the Republic of China and not those of any other jurisdictions. The standards, procedures and practices to review such consolidated financial statements are those generally accepted and applied in the Republic of China.

The independent auditors’ review report and the accompanying consolidated financial statements are the English translation of the Chinese version prepared and used in the Republic of China. If there is any conflict between, or any difference in the interpretation of the English and Chinese language independent auditors’ review report and consolidated financial statements, the Chinese version shall prevail.

(English Translation of Consolidated Financial Statements Originally Issued in Chinese)

SCI PHARMTECH, INC. AND SUBSIDIARIES**Consolidated Balance Sheets****March 31, 2024, December 31, 2023, and March 31, 2023****(expressed in thousands of New Taiwan dollars)**

	March 31, 2024		December 31, 2023		March 31, 2023			March 31, 2024		December 31, 2023		March 31, 2023			
	Assets	Amount	%	Amount	%	Amount		%	Liabilities and Equity	Amount	%	Amount	%	Amount	%
Current assets:								Current liabilities:							
1100 Cash and cash equivalents (note 6(a))	\$	915,963	14	942,057	14	99,605	2	2100 Total short-term borrowings (note 6(j))	\$	66,000	1	175,000	3	425,000	8
1110 Current financial assets at fair value through profit or loss (note 6(b))		78,399	1	88,998	1	97,401	2	2170 Notes and accounts payable		77,385	1	44,251	1	46,815	1
1170 Notes and accounts receivable, net (notes 6(d) and 6(s))		253,031	4	307,369	5	254,530	5	2130 Current contract liabilities (note 6(s))		37,118	1	38,367	1	31,450	1
1206 Other receivables		243	-	151	-	141	-	2200 Other payables		148,669	2	169,538	3	168,863	3
1310 Inventories, net (note 6(e))		601,181	9	529,533	8	521,057	10	2213 Payables on contractors and equipment		26,550	1	68,840	1	158,637	3
1470 Other current assets		75,049	1	85,131	1	60,985	1	2230 Current tax liabilities		22,817	-	11,536	-	19,112	-
		1,923,866	29	1,953,239	29	1,033,719	20	2250 Current provisions (notes 6(m) and 10)		23,300	-	29,058	-	40,612	1
Non-current assets:								2280 Current lease liabilities (note 6(l))		1,890	-	1,946	-	485	-
1518 Non-current financial assets at fair value through other comprehensive income (note 6(c))		94,250	1	96,814	2	63,212	1	2300 Other current liabilities (note 6(d))		15,605	-	11,351	-	5,251	-
1550 Investments accounted for using equity method (note 6(f))		140,690	2	144,808	2	139,320	3	2322 Long-term borrowings, current portion (note 6(k))		46,831	1	20,000	-	-	-
1600 Property, plant and equipment (notes 6(g), 7 and 8)		3,916,646	59	3,906,993	58	3,449,235	66			466,165	7	569,887	9	896,225	17
1755 Right-of-use assets (note 6(h))		4,265	-	4,772	-	610	-	Non-Current liabilities:							
1761 Investment property, land (notes 6(i) and 7)		228,012	3	228,012	4	228,012	4	2541 Long-term borrowings (note 6(k))		912,706	14	842,670	13	502,179	10
1780 Intangible assets		44,044	1	46,147	1	52,468	1	2580 Non-current lease liabilities (note 6(l))		2,414	-	2,858	-	131	-
1840 Deferred tax assets		153,277	2	153,277	2	167,252	3	2570 Deferred tax liabilities		146,000	2	146,000	2	103,811	2
1900 Other non-current assets (note 6(g))		193,808	3	156,679	2	82,533	2	2630 Deferred income (note 6(k))		7,321	-	6,837	-	4,626	-
		4,774,992	71	4,737,502	71	4,182,642	80	2640 Provisions for employee benefits, non-current		21,354	-	21,536	-	19,238	-
								2600 Total other non-current liabilities (note 7)		1,000	-	1,000	-	1,000	-
										1,090,795	16	1,020,901	15	630,985	12
								Total liabilities		1,556,960	23	1,590,788	24	1,527,210	29
								Equity attributable to owners of parent (note 6(p)):							
								3100 Ordinary Share		1,195,087	18	1,195,087	18	953,824	18
								3200 Capital surplus		2,233,590	33	2,233,590	33	1,357,127	26
								3310 Legal reserve		462,435	7	462,435	7	431,874	8
								3320 Special reserve		54,727	1	54,727	1	48,929	1
								3350 Unappropriated retained earnings		1,173,166	18	1,128,657	17	955,635	19
								3400 Other components of equity		22,893	-	25,457	-	(58,238)	(1)
								Total equity		5,141,898	77	5,099,953	76	3,689,151	71
Total assets	\$	6,698,858	100	6,690,741	100	5,216,361	100	Total liabilities and equity	\$	6,698,858	100	6,690,741	100	5,216,361	100

See accompanying notes to consolidated financial statements.

(English Translation of Consolidated Financial Statements Originally Issued in Chinese)
SCI PHARMTECH, INC. AND SUBSIDIARIES
Consolidated Statements of Comprehensive Income
For the three months ended March 31, 2024 and 2023
(expressed in Thousands of New Taiwan Dollars, except for earnings per share)

		For the three months ended March 31,			
		2024		2023	
		Amount	%	Amount	%
4110	Sales revenue (note 6(s))	\$ 309,879	100	341,779	100
5110	Cost of sales (notes 6(e), 6(n) and 12)	218,006	70	218,767	64
5900	Gross profit	91,873	30	123,012	36
Operating expenses (notes 6(n) and 12):					
6100	Selling expenses	17,377	6	14,800	4
6200	Administrative expenses	18,862	6	17,473	5
6300	Research and development expenses	10,604	3	11,958	4
		46,843	15	44,231	13
6900	Net operating income	45,030	15	78,781	23
Non-operating income and expenses:					
7101	Interest income	534	-	397	-
7190	Other income (note 7)	2,795	1	1,816	1
7235	Gains (losses) on financial assets at fair value through profit or loss	(828)	-	2,294	1
7510	Interest expense (note 6(l))	(1,499)	(1)	(1,706)	(1)
7590	Miscellaneous disbursements	(111)	-	(85)	-
7630	Foreign exchange gains (losses)	14,040	4	(776)	-
7770	Share of loss of associates and joint ventures accounted for using equity method, net (note 6(f))	(4,118)	(1)	(1,997)	(1)
		10,813	3	(57)	-
7900	Profit before tax	55,843	18	78,724	23
7950	Less: Income tax expenses (note 6(o))	11,334	4	15,286	4
8200	Profit	44,509	14	63,438	19
8300	Other comprehensive income:				
8310	Items that may not be reclassified subsequently to profit or loss:				
8316	Unrealized gains (losses) from investments in equity instruments measured at fair value through other comprehensive income	(2,564)	(1)	(3,511)	(1)
8349	Less: Income tax related to components of other comprehensive income that will not be reclassified to profit or loss (note 6(o))	-	-	-	-
8300	Other comprehensive income, net	(2,564)	(1)	(3,511)	(1)
8500	Total comprehensive income	\$ 41,945	13	59,927	18
Earnings per share (note 6(r)):					
9750	Basic earnings per share	\$ 0.37		0.59	
9850	Diluted earnings per share	\$ 0.37		0.59	

See accompanying notes to consolidated financial statements.

(English Translation of Consolidated Financial Statements Originally Issued in Chinese)

SCI PHARMTECH, INC. AND SUBSIDIARIES**Consolidated Statements of Changes in Equity****For the three months ended March 31, 2024 and 2023****(expressed in Thousands of New Taiwan Dollars)**

	<u>Equity attributable to owners of parent</u>					<u>Other equity interest</u>	<u>Total equity</u>	
	<u>Ordinary shares</u>	<u>Capital surplus</u>	<u>Retained earnings</u>		<u>Unappropriated retained earnings</u>			<u>Unrealized gains (losses) from financial assets measured at fair value through other comprehensive income</u>
			<u>Legal reserve</u>	<u>Special reserve</u>				
Balance at January 1, 2023	\$ 953,824	1,357,127	431,874	48,929	892,197	(54,727)	3,629,224	
Profit for the three months ended March 31, 2023	-	-	-	-	63,438	-	63,438	
Other comprehensive income for the three months ended March 31, 2023	-	-	-	-	-	(3,511)	(3,511)	
Total comprehensive income for the three months ended March 31, 2023	-	-	-	-	63,438	(3,511)	59,927	
Balance at March 31, 2023	<u>\$ 953,824</u>	<u>1,357,127</u>	<u>431,874</u>	<u>48,929</u>	<u>955,635</u>	<u>(58,238)</u>	<u>3,689,151</u>	
Balance at January 1, 2024	\$ 1,195,087	2,233,590	462,435	54,727	1,128,657	25,457	5,099,953	
Profit for the three months ended March 31, 2024	-	-	-	-	44,509	-	44,509	
Other comprehensive income for the three months ended March 31, 2024	-	-	-	-	-	(2,564)	(2,564)	
Total comprehensive income for the three months ended March 31, 2024	-	-	-	-	44,509	(2,564)	41,945	
Balance at March 31, 2024	<u>\$ 1,195,087</u>	<u>2,233,590</u>	<u>462,435</u>	<u>54,727</u>	<u>1,173,166</u>	<u>22,893</u>	<u>5,141,898</u>	

See accompanying notes to consolidated financial statements.

(English Translation of Consolidated Financial Statements Originally Issued in Chinese)

SCI PHARMTECH, INC. AND SUBSIDIARIES**Consolidated Statements of Cash Flows****For the three months ended March 31, 2024 and 2023****(expressed in Thousands of New Taiwan Dollars)**

	For the three months ended March 31	
	2024	2023
Cash flows from (used in) operating activities:		
Profit before tax	\$ 55,843	78,724
Adjustments for:		
Adjustments to reconcile profit (loss):		
Depreciation expense	49,034	29,732
Amortization expense	2,103	2,114
Net loss (profit) on financial assets or liabilities at fair value through profit or loss	828	(2,294)
Interest expense	1,499	1,706
Interest income	(534)	(397)
Share of loss of associates and joint ventures accounted for using equity method	4,118	1,997
Others	1,522	-
Total adjustments to reconcile profit	<u>58,570</u>	<u>32,858</u>
Changes in operating assets and liabilities:		
Decrease (increase) in notes and accounts receivable	54,338	(80,965)
Increase in inventories	(71,648)	(7,627)
Decrease in other receivables and other current assets	9,998	29,904
Decrease in contract liabilities	(1,249)	(323)
Increase (decrease) in notes and accounts payable	33,134	(1,821)
Decrease in other payable	(20,869)	(127,154)
Decrease in provisions	(5,758)	(70,772)
Increase in other current liabilities	4,254	27
Decrease in provision for employee benefits, non-current	(182)	(292)
Total changes in operating assets and liabilities	<u>2,018</u>	<u>(259,023)</u>
Total adjustments	<u>60,588</u>	<u>(226,165)</u>
Cash flow from (used in) operations	116,431	(147,441)
Interest received	534	397
Interest paid	(1,499)	(1,706)
Income taxes paid	(61)	(36)
Net cash flows from (used in) operating activities	<u>115,405</u>	<u>(148,786)</u>
Cash flows from (used in) investing activities:		
Proceeds from disposal of financial assets at fair value through profit or loss	9,771	2,438
Acquisition of property, plant and equipment	(101,102)	(222,086)
Increase in prepayments of property, plant and equipment	(37,129)	(81,302)
Net cash flows from (used in) investing activities	<u>(128,460)</u>	<u>(300,950)</u>
Cash flows from (used in) financing activities:		
(Decrease) increase in short-term borrowings	(109,000)	313,000
Proceeds from long-term borrowings	96,461	69,920
Payment of lease liabilities	(500)	(407)
Net cash flows from (used in) financing activities	<u>(13,039)</u>	<u>382,513</u>
Net decrease in cash and cash equivalents	(26,094)	(67,223)
Cash and cash equivalents at beginning of period	942,057	166,828
Cash and cash equivalents at end of period	<u>\$ 915,963</u>	<u>99,605</u>

See accompanying notes to consolidated financial statements.

(English Translation of Consolidated Financial Statements Originally Issued in Chinese)

SCI PHARMTECH, INC. AND SUBSIDIARIES

Notes to the Consolidated Financial Statements

March 31, 2024 and 2023

(Expressed in Thousands of New Taiwan Dollars, Unless Otherwise Specified)

(1) Company history

SCI Pharmtech, Inc. (the “Company”) was incorporated in September 18, 1987 as a company limited by shares and registered under the Ministry of Economic Affairs, R.O.C. The major business activities of the Company are the research and development, manufacture and sale of Active Pharmaceutical Ingredients (“API”), Intermediates, specialty chemicals. The consolidated financial statements of the Company comprise the Company and its subsidiaries (together referred to as the “Group” and individually as the “Group entities”). Please refer to note 4(b) for related information of the Group primarily business activities. Mercuries & Associates, Holding Ltd. is the parent company of the Company.

(2) Approval date and procedures of the consolidated financial statements

These consolidated financial statements were authorized for issuance by the Board of Directors on May 9, 2024.

(3) New standards, amendments and interpretations adopted:

- (a) The impact of the IFRS Accounting Standards endorsed by the Financial Supervisory Commission, R.O.C. which have already been adopted.

The Group has initially adopted the following new amendments, which do not have a significant impact on its consolidated financial statements, from January 1, 2024:

- Amendments to IAS 1 “Classification of Liabilities as Current or Non-current”
- Amendments to IAS 1 “Non-current Liabilities with Covenants”
- Amendments to IAS 7 and IFRS 7 “Supplier Finance Arrangements”
- Amendments to IFRS 16 “Lease Liability in a Sale and Leaseback”

- (b) The impact of IFRS issued by IASB but not yet endorsed by the FSC

The following new and amended standards, which may be relevant to the Group, have been issued by the International Accounting Standards Board (IASB), but have yet to be endorsed by the FSC:

Standards or Interpretations	Content of amendment	Effective date per IASB
IFRS 18 “Presentation and Disclosure in Financial Statements”	The new standard introduces three categories of income and expenses, two income statement subtotals and one single note on management performance measures. The three amendments, combined with enhanced guidance on how to disaggregate information, set the stage for better and more consistent information for users, and will affect all the entities.	January 1, 2027

(Continued)

SCI PHARMTECH, INC. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

Standards or Interpretations	Content of amendment	Effective date per IASB
IFRS 18 “Presentation and Disclosure in Financial Statements”	<ul style="list-style-type: none"> ● A more structured income statement: under current standards, companies use different formats to present their results, making it difficult for investors to compare financial performance across companies. The new standard promotes a more structured income statement, introducing a newly defined ‘operating profit’ subtotal and a requirement for all income and expenses to be allocated between three new distinct categories based on a company’s main business activities. ● Management performance measures (MPMs): the new standard introduces a definition for management performance measures, and requires companies to explain in a single note to the financial statements why the measure provides useful information, how it is calculated and reconcile it to an amount determined under IFRS Accounting Standards. ● Greater disaggregation of information: the new standard includes enhanced guidance on how companies group information in the financial statements. This includes guidance on whether information is included in the primary financial statements or is further disaggregated in the notes. 	January 1, 2027

The Group is evaluating the impact on its consolidated financial position and consolidated financial performance upon the initial adoption of the abovementioned standards or interpretations. The results thereof will be disclosed when the Group completes its evaluation.

(Continued)

SCI PHARMTECH, INC. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

The Group does not expect the following other new and amended standards, which have yet to be endorsed by the FSC, to have a significant impact on its consolidated financial statements:

- Amendments to IFRS 10 and IAS 28 “Sale or Contribution of Assets Between an Investor and Its Associate or Joint Venture”
- IFRS 17 “Insurance Contracts” and amendments to IFRS 17 “Insurance Contracts”
- Amendments to IFRS 17 “Initial Application of IFRS 17 and IFRS 9 – Comparative Information”
- Amendments to IAS21 “Lack of Exchangeability”

(4) Summary of material accounting policies:

(a) Statement of compliance

These consolidated financial statements have been prepared in accordance with the preparation and guidelines of IAS 34 “Interim Financial Reporting” which are endorsed and issued into effect by FSC, and do not include all of the information required by the Regulations and International Financial Reporting Standards, International Accounting Standards, IFRIC Interpretations and SIC Interpretations endorsed and issued into effect by the FSC (hereinafter referred to IFRS endorsed by the FSC) for a complete set of the annual consolidated financial statements.

Except the following accounting policies mentioned below, the significant accounting policies adopted in the consolidated financial statements are the same as those in the consolidated financial statement for the year ended December 31, 2023. For the related information, please refer to note 4 of the consolidated financial statements for the year ended December 31, 2023.

(b) Basis of Consolidation

<u>Name of investor</u>	<u>Name of subsidiary</u>	<u>Principal activity</u>	<u>Shareholding</u>		
			<u>March 31, 2024</u>	<u>December 31, 2023</u>	<u>March 31, 2023</u>
The Company	Yushan Pharmaceuticals Inc. (Yushan)	The research and development, manufacture and sale of API	100.00 %	100.00 %	100.00 %

(c) Classification of current and non-current assets and liabilities

The Group classifies the asset as current under one of the following criteria, and all other assets are classified as non current.

- (i) It expects to realize the asset, or intends to sell or consume it, in its normal operating cycle;
- (ii) It holds the asset primarily for the purpose of trading;
- (iii) It expects to realize the asset within twelve months after the reporting period; or

(Continued)

SCI PHARMTECH, INC. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

- (iv) The asset is cash or a cash equivalent (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period.

The Group classifies the liability as current under one of the following criteria, and all other liabilities are classified as non current.

- (i) It expects to settle the liability in its normal operating cycle;
- (ii) It holds the liability primarily for the purpose of trading
- (iii) The liability is due to be settled within twelve months after the reporting period; or
- (iv) It does not have the right at the end of the reporting period to defer settlement of the liability for at least twelve months after the reporting period.

(d) Employee benefits

The pension cost in the interim period was calculated and disclosed on a year-to-date basis by using the actuarially determined pension cost rate at the end of the prior fiscal year.

(e) Income taxes

The income tax expenses have been prepared and disclosed in accordance with paragraph B12 of International Financial Reporting Standards 34, Interim Reporting.

Income tax expenses for the period are best estimated by multiplying pre-tax income for the interim reporting period by the effective annual tax rate as forecasted by the management. This should be recognized fully as tax expense for the current period.

Temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and their respective tax bases shall be measured based on the tax rates that have been enacted or substantively enacted at the time of the asset or liability is recovered or settled, and be recognized directly in equity or other comprehensive income as tax expense.

(5) Significant accounting assumptions and judgments, and major sources of estimation uncertainty:

The preparation of the consolidated financial statements in conformity with the Regulations and IFRSs (in accordance with IAS 34 “Interim Financial Reporting” and endorsed by the FSC) requires management to make judgments, estimates and assumptions that affect the application of the accounting policies and the reported amount of assets, liabilities, income and expenses. Actual results may differ from these estimates.

The preparation of the consolidated interim financial statements, estimates and underlying assumptions are reviewed on an ongoing basis which are in conformity with the consolidated financial statements for the year ended December 31, 2023. For the related information, please refer to note 5 of the consolidated financial statements for the year ended December 31, 2023.

(Continued)

SCI PHARMTECH, INC. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

(6) Explanation of significant accounts:

Except for the following disclosures, there is no significant difference as compared with those disclosed in the consolidated financial statements for the year ended December 31, 2023. Please refer to note 6 of the 2023 annual consolidated financial statements.

(a) Cash and cash equivalents

	<u>March 31, 2024</u>	<u>December 31, 2023</u>	<u>March 31, 2023</u>
Cash on hand	\$ 538	499	541
Checking accounts and demand deposits	879,277	907,102	68,657
Time deposits	<u>36,148</u>	<u>34,456</u>	<u>30,407</u>
Cash and cash equivalents in the consolidated statement of cash flows	<u>\$ 915,963</u>	<u>942,057</u>	<u>99,605</u>

(i) The Group did not provide cash and cash equivalents as collateral for its loans.

(ii) Please refer to note 6(u) for the interest rate risk and sensitivity analysis of the financial assets and liabilities of the Group.

(b) Financial assets at fair value through profit or loss

	<u>March 31, 2024</u>	<u>December 31, 2023</u>	<u>March 31, 2023</u>
Mandatorily measured at fair value through profit or loss:			
Non-derivative financial assets			
Beneficiary certificate	\$ 1,055	1,052	1,042
Stocks listed on domestic markets	<u>77,344</u>	<u>87,946</u>	<u>96,359</u>
Total	<u>\$ 78,399</u>	<u>88,998</u>	<u>97,401</u>

The Group did not provide any aforementioned financial assets as collateral for its loans as of March 31, 2024, December 31 and March 31, 2023, respectively.

(c) Financial asset at fair value through other comprehensive income, non-current:

	<u>March 31, 2024</u>	<u>December 31, 2023</u>	<u>March 31, 2023</u>
Financial assets at fair value through other comprehensive income:			
Stocks listed on domestic markets	\$ 94,250	96,814	-
Emerging stocks	<u>-</u>	<u>-</u>	<u>63,212</u>
	<u>\$ 94,250</u>	<u>96,814</u>	<u>63,212</u>

(Continued)

SCI PHARMTECH, INC. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

- (i) The Group designated the investments shown above as equity securities as at fair value through other comprehensive income because these equity securities represent those investments that the Group intends to hold for long-term for strategic purposes.
- (ii) There was no significant change for financial assets at fair value through other comprehensive income, non-current for the three months ended March 31, 2024 and 2023. Please refer to note 6(c) of the consolidated financial statements for the year ended December 31, 2023.
- (iii) Energenesis Biomedical Co., Ltd., was originally an emerging company and became listed in June 2023.
- (iv) Please refer to note 6(u) for market risk of the Group.
- (v) As of March 31, 2024, December 31 and March 31, 2023, the Group did not provide any aforementioned financial assets as collateral for its loans.
- (d) Notes and accounts receivable

	<u>March 31,</u> <u>2024</u>	<u>December 31,</u> <u>2023</u>	<u>March 31,</u> <u>2023</u>
Notes receivable	\$ -	-	536
Accounts receivable	253,031	307,369	253,994
Less: Loss allowance	-	-	-
	<u>\$ 253,031</u>	<u>307,369</u>	<u>254,530</u>

The Group applies the simplified approach to provide for its expected credit losses, i.e. the use of lifetime expected loss provision for all receivables, as well as incorporated forward looking information, including the reasonable prediction of historical credit loss experience and future economic situation (macroeconomic and relevant industry information). The loss allowance provision was determined as follows:

	<u>March 31, 2024</u>		
	<u>Gross carrying amount</u>	<u>Rate of loss allowance provision</u>	<u>Loss allowance provision</u>
Current	\$ 224,219	-	-
1 to 30 days past due	7,126	-	-
31 to 60 days past due	19,753	-	-
61 to 90 days past due	1,933	-	-
	<u>\$ 253,031</u>		<u>-</u>

(Continued)

SCI PHARMTECH, INC. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

	December 31, 2023		
	Gross carrying amount	Rate of loss allowance provision	Loss allowance provision
Current	\$ 184,452	-	-
1 to 30 days past due	28,289	-	-
31 to 60 days past due	25,539	-	-
61 to 90 days past due	-	-	-
91 to 180 days past due	14	-	-
181 to 270 days past due	69,075	-	-
	\$ 307,369		-
		March 31, 2023	
	Gross carrying amount	Rate of loss allowance provision	Loss allowance provision
Current	\$ 247,006	-	-
1 to 30 days past due	-	-	-
31 to 60 days past due	-	-	-
61 to 90 days past due	2,745	-	-
91 to 180 days past due	-	-	-
181 to 270 days past due	-	-	-
271 to 360 days past due	-	-	-
More than 360 days past due	4,779 (note)	-	-
	\$ 254,530		-

Note: The account receivable has already estimated as refund liabilities for short-term sales discounts and allowances. (recorded as other current liabilities)

The movement in the allowance for notes and trade receivable was as follows:

	For the three months ended March 31,	
	2024	2023
Balance at January 1 (Balance at March 31)	\$ -	-

As of March 31, 2024, December 31 and March 31, 2023, the Group did not provide any aforementioned notes and accounts receivable as collaterals for its loans.

(Continued)

SCI PHARMTECH, INC. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

(e) Inventories

	<u>March 31, 2024</u>	<u>December 31, 2023</u>	<u>March 31, 2023</u>
Raw materials	\$ 94,209	92,404	130,719
Work in progress	109,117	85,692	62,000
Finished goods	<u>397,855</u>	<u>351,437</u>	<u>328,338</u>
	<u><u>\$ 601,181</u></u>	<u><u>529,533</u></u>	<u><u>521,057</u></u>

Inventory cost recognized as operating costs for the three months ended March 31, 2024 and 2023 were as follows:

	<u>For the three months ended March 31,</u>	
	<u>2024</u>	<u>2023</u>
Inventory that has been sold	\$ 190,039	190,323
Write-down of inventories (Reversal of write downs)	(22,506)	9,634
Loss on disposal of inventories	18,847	1,381
Unallocated production overheads	<u>31,626</u>	<u>17,429</u>
	<u><u>\$ 218,006</u></u>	<u><u>218,767</u></u>

As of March 31, 2024, December 31 and March 31, 2023, the Group did not provide any inventories as collaterals for its loans.

(f) Investments accounted for using equity method

The components of investments accounted for using equity method at the reporting date were as follows:

	<u>March 31, 2024</u>	<u>December 31, 2023</u>	<u>March 31, 2023</u>
Associates	<u>\$ 140,690</u>	<u>144,808</u>	<u>139,320</u>

(i) There was no significant change for investments accounted for using the equity method for the three months ended March 31, 2024 and 2023. For the related information, please refer to note 6(g) of the consolidated financial statements for the year ended December 31, 2023.

(ii) The Group's financial information on investments accounted for using equity method that are individually insignificant was as follows:

	<u>March 31, 2024</u>	<u>December 31, 2023</u>	<u>March 31, 2023</u>
Carrying amount of individually insignificant associates' equity	<u>\$ 140,690</u>	<u>144,808</u>	<u>139,320</u>

(Continued)

SCI PHARMTECH, INC. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

	For the three months ended March 31,	
	2024	2023
Attributable to the Group:		
Profit (loss)	\$ (4,118)	(1,997)
Other comprehensive income (loss)	-	-
Total comprehensive income (loss)	\$ (4,118)	(1,997)

(iii) Pledge to secure

The Group did not provide any investment accounted for using equity method as collaterals for its loans.

(iv) The investments were accounted for using the equity method, and the share of profit or loss and other comprehensive income of those investments were calculated based on the financial statements that have not been reviewed.

(g) Property, plant and equipment

The cost, depreciation, and impairment of the property, plant and equipment of the Group , were as follows:

	Land	Buildings and construction	Machinery and equipment	Office equipment	Other	Prepayment for equipment and construction in progress	Total
Cost:							
Balance on January 1, 2024	\$ 687,883	707,002	1,714,324	58,337	12,968	1,564,525	4,745,039
Additions	-	-	18,056	-	-	41,646	59,702
Transferred in (out)	-	15,902	442,225	271	-	(459,920)	(1,522)
Balance on March 31, 2024	\$ 687,883	722,904	2,174,605	58,608	12,968	1,146,251	4,803,219
Balance on January 1, 2023	\$ 687,883	700,232	1,116,895	55,466	12,968	1,323,065	3,896,509
Additions	-	-	9,669	-	-	210,463	220,132
Transferred in (out)	-	-	36,237	246	-	28,805	65,288
Balance on March 31, 2023	\$ 687,883	700,232	1,162,801	55,712	12,968	1,562,333	4,181,929
Depreciation and impairments loss:							
Balance on January 1, 2024	\$ -	311,735	489,788	28,553	7,970	-	838,046
Depreciation	-	6,474	40,639	1,154	260	-	48,527
Balance on March 31, 2024	\$ -	318,209	530,427	29,707	8,230	-	886,573
Balance on January 1, 2023	\$ -	287,084	385,715	23,635	6,931	-	703,365
Depreciation	-	6,138	21,701	1,230	260	-	29,329
Balance on March 31, 2023	\$ -	293,222	407,416	24,865	7,191	-	732,694

(Continued)

SCI PHARMTECH, INC. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

	<u>Land</u>	<u>Buildings and construction</u>	<u>Machinery and equipment</u>	<u>Office equipment</u>	<u>Other</u>	<u>Prepayment for equipment and construction in progress</u>	<u>Total</u>
Carrying amounts:							
Balance on January 1, 2024	\$ <u>687,883</u>	<u>395,267</u>	<u>1,224,536</u>	<u>29,784</u>	<u>4,998</u>	<u>1,564,525</u>	<u>3,906,993</u>
Balance on March 31, 2024	\$ <u>687,883</u>	<u>404,695</u>	<u>1,644,178</u>	<u>28,901</u>	<u>4,738</u>	<u>1,146,251</u>	<u>3,916,646</u>
Balance on January 1, 2023	\$ <u>687,883</u>	<u>413,148</u>	<u>731,180</u>	<u>31,831</u>	<u>6,037</u>	<u>1,323,065</u>	<u>3,193,144</u>
Balance on March 31, 2023	\$ <u>687,883</u>	<u>407,010</u>	<u>755,385</u>	<u>30,847</u>	<u>5,777</u>	<u>1,562,333</u>	<u>3,449,235</u>

Except for the following, the information on significant transactions of the Group's property, plant and equipment, please refer to note 6(h) of the consolidated financial statements for the year ended December 31, 2023.

- (i) As of March 31, 2024, December 31 and March 31, 2023, the Group's prepayments for equipment purchases amounted to \$192,888, \$155,759 and \$81,723, respectively, which were recorded as other non-current assets.
- (ii) As of March 31, 2024, December 31 and March 31, 2023, part of the property, plant and equipment of the Group had been pledged as collateral. Please refer to note 8 for the details.
- (h) Right-of-use assets

The Group leases many assets including land, company cars and copy machines. Information about leases for which the Group as a lessee is presented below:

	<u>Land</u>	<u>Others</u>	<u>Total</u>
Cost:			
Balance on January 1, 2024 (same as balance on March 31, 2024)	\$ <u>3,566</u>	<u>2,626</u>	<u>6,192</u>
Balance on January 1, 2023	\$ -	4,922	4,922
Reductions	-	(868)	(868)
Balance on March 31, 2023	\$ -	<u>4,054</u>	<u>4,054</u>
Accumulated depreciation:			
Balance on January 1, 2024	\$ 475	945	1,420
Depreciation for the period	179	328	507
Balance on March 31, 2024	\$ <u>654</u>	<u>1,273</u>	<u>1,927</u>
Balance on January 1, 2023	\$ -	3,909	3,909
Depreciation for the period	-	403	403
Reductions	-	(868)	(868)
Balance on March 31, 2023	\$ -	<u>3,444</u>	<u>3,444</u>

(Continued)

SCI PHARMTECH, INC. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

	Land	Others	Total
Carrying amount:			
Balance on January 1, 2024	\$ <u>3,091</u>	<u>1,681</u>	<u>4,772</u>
Balance on March 31, 2024	\$ <u>2,912</u>	<u>1,353</u>	<u>4,265</u>
Balance on January 1, 2023	\$ <u>-</u>	<u>1,013</u>	<u>1,013</u>
Balance on March 31, 2023	\$ <u>-</u>	<u>610</u>	<u>610</u>

(i) Investments property

- (i) Investment property, with a carrying amount of \$228,012, with lease that has fixed rental income and contains an initial non-cancellable lease term of 50 years (extendable upon maturity) based on the agreement, comprises lands owned by the Group.
- (ii) There were no significant additions, disposal, or recognition and reversal of impairment losses of investment property for the three months ended March 31, 2024 and 2023. Please refer to note 6(j) of the consolidated financial statements for the year ended December 31, 2023.
- (iii) There were no significant changes in the fair value of the Group's investment property as disclosed in note 6(j) of the consolidated financial statements for the year ended December 31, 2023.
- (iv) The Group rented out investment property for related parties. Please refer to note 7 for the details of rental income.
- (v) The Group did not provide any investment properties as collaterals for its loan.

(j) Short-term borrowings

The details of short-term borrowings were as following:

	March 31, 2024	December 31, 2023	March 31, 2023
Unsecured bank loans	\$ 66,000	125,000	395,000
Secured bank loans	-	50,000	30,000
Total	\$ <u>66,000</u>	<u>175,000</u>	<u>425,000</u>
Unused short-term credit lines	\$ <u>664,000</u>	<u>695,000</u>	<u>365,000</u>
Range of interest rates	<u>1.73%~2.225%</u>	<u>1.7%~2.1%</u>	<u>1.6%~1.975%</u>

- (i) For the collateral of the Group's assets for short-term borrowings, please refer to note 8.
- (ii) For the information on the Group's exposure to the interest rate risk and liquidity risk, please refer to note 6(u).

(Continued)

SCI PHARMTECH, INC. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

(k) Long-term borrowings

The details of long-term borrowings were as following:

	<u>March 31, 2024</u>	<u>December 31, 2023</u>	<u>March 31, 2023</u>
Secured bank loans – Maturity year 2025.3~2027.2	\$ 783,033	686,572	375,687
Unsecured bank loans – Maturity year 2025.11 and 2026.9	180,000	180,000	130,000
Less: current portion	(46,831)	(20,000)	-
Less: Deferred income	<u>(3,496)</u>	<u>(3,902)</u>	<u>(3,508)</u>
	<u>\$ 912,706</u>	<u>842,670</u>	<u>502,179</u>
Unused credit lines	<u>\$ 266,967</u>	<u>363,428</u>	<u>624,313</u>
Range of interest rates	<u>1.675%~2.05%</u>	<u>1.05%~1.925%</u>	<u>0.8%~1.8%</u>

- (i) For the three months ended March 31, 2024 and 2023, the Group had the additional long-term borrowings amounting to \$96,461 and \$69,920, respectively, and the repayment amounted to \$0.
- (ii) The Group's application for a low-interest loan for the construction of plants, purchasing equipment, and support medium-term working capital, had been approved by the National Development Fund, Executive Yuan in 2022, with Mega International Commercial Bank providing the non-revolving loan of \$1,000,000, which was recognized and measured by using the market rates, with the margin interests calculated by using the rates between the actual rates and the market rates, recognized as deferred income, based on the Government grants. As of March 31, 2024, the Group had used the credit amount of \$783,033.
- (iii) For the collateral for long-term borrowings, please refer to note 8.

(l) Lease liabilities

The carrying amount of lease liabilities was as follows:

	<u>March 31, 2024</u>	<u>December 31, 2023</u>	<u>March 31, 2023</u>
Current	<u>\$ 1,890</u>	<u>1,946</u>	<u>485</u>
Non-current	<u>\$ 2,414</u>	<u>2,858</u>	<u>131</u>

Please refer to note 6(u) for maturity analysis.

(Continued)

SCI PHARMTECH, INC. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

	For the three months ended	
	March 31,	
	2024	2023
The amounts recognized in profit or loss were as follows:		
Interest on lease liabilities	\$ <u>23</u>	<u>3</u>
Expenses relating to short-term leases	\$ <u>80</u>	<u>194</u>
Variable lease payments not included in the measurement of lease liabilities	\$ <u>-</u>	<u>6</u>
Expense relating to leases of low-value assets, excluding short-term leases of low-value assets	\$ <u>194</u>	<u>140</u>
	For the three months ended	
	March 31,	
	2024	2023
The amounts recognized in the statement of cash flows for the Group were as follows:		
Total cash outflow for leases	\$ <u>797</u>	<u>750</u>

(i) The Group leases land, company cars and copy machines: The leases typically run for a period of three to six years.

(ii) Other leases

The Group leases vehicles and office equipment. These leases are short-term or leases of low-value items. The Group has elected not to recognize right-of-use assets and lease liabilities for these leases.

(m) Provisions

Except for the following disclosure, there was no significant change for provisions for the three months ended March 31, 2024 and 2023. For the related information, please refer to note 6(o) of the consolidated financial statements for the year ended December 31, 2023.

	Environmental protection costs	Fire disaster indemnity	Total
Balance on January 1, 2024	\$ 29,058	-	29,058
Provisions made during the year	6,289	-	6,289
Provisions used during the year	<u>(12,047)</u>	<u>-</u>	<u>(12,047)</u>
Balance on March 31, 2024	<u>\$ 23,300</u>	<u>-</u>	<u>23,300</u>
Balance on January 1, 2023	\$ 43,225	68,159	111,384
Provisions used during the year	<u>(9,823)</u>	<u>(60,949)</u>	<u>(70,772)</u>
Balance on March 31, 2023	<u>\$ 33,402</u>	<u>7,210</u>	<u>40,612</u>

Please refer to note 10 for the above fire indemnity.

(Continued)

SCI PHARMTECH, INC. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

(n) Employee benefits

(i) Defined benefit plans

Management believes that there was no material volatility of the market, no material reimbursement and settlement or other material one-time events since prior fiscal year. As a result, the pension cost in the accompanying interim period was measured and disclosed according to the actuarial report as of December 31, 2023 and 2022.

The expenses recognized in profit or loss for the Group were as follows:

	For the three months ended March 31,	
	2024	2023
Operating cost	\$ 287	136
Operating expenses	110	70
Total	\$ 397	206

(ii) Defined contribution plans

The Group's expenses under the pension plan cost to the Bureau of Labor Insurance were as follows:

	For the three months ended March 31,	
	2024	2023
Operating cost	\$ 1,620	1,325
Selling expenses	532	474
Total	\$ 2,152	1,799

(o) Income taxes

(i) The Group's income tax expense in the interim financial statements is measured and disclosed accordance to paragraph B12 of IAS 34 "Interim Financial Reporting".

(ii) The Group's income tax expenses for the three months ended March 31, 2024 and 2023 were calculated as follows:

	For the three months ended March 31,	
	2024	2023
Current income tax expense	\$ 11,334	15,286

(iii) For the three months ended March 31, 2024 and 2023, the Group did not recognize income tax expense in equity and other comprehensive income.

(Continued)

SCI PHARMTECH, INC. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

(iv) Examination and approval

The ROC tax authorities have examined the Company's and Yushan's income tax returns through 2022.

(p) Capital and other equity

Except for the following disclosure, there was no significant change for capital and other equity for the periods from January 1 to March 31, 2024 and 2023. For the related information, please refer to note 6(r) of the consolidated financial statements for the year ended December 31, 2023.

(i) Capital surplus

The balances of capital surplus as of March 31, 2024, December 31 and March 31, 2023 were as follows:

	<u>March 31, 2024</u>	<u>December 31, 2023</u>	<u>March 31, 2023</u>
Additional paid-in capital	\$ 2,127,990	2,127,990	1,270,247
Cash capital increase reserved for employees' subscription	18,720	18,720	-
Gain on disposal of assets	980	980	980
Stock options	71,530	71,530	71,530
Changes in equity of associates and joint ventures accounted for using equity method	8,788	8,788	8,788
Employee stock options	<u>5,582</u>	<u>5,582</u>	<u>5,582</u>
	<u>\$ 2,233,590</u>	<u>2,233,590</u>	<u>1,357,127</u>

(ii) Retained Earnings

The Company's article of incorporation stipulates that Company's net earnings should first be used to offset the prior years' deficits, if any, after paying any income taxes. Of the remaining balance, 10% is to be appropriated as legal reserve, and special reserves are supposed to set aside in accordance with the relevant regulations or as required by the government. And then any undistributed retained earnings shall be distributed according to the distribution plan proposed by the Board of Directors and submitted to the stockholders' meeting for approval.

According to the Company's dividend policy, the type of dividends should be determined after considering the Company's capital and financial structure, operating conditions, operating surplus, industrial characteristics and cycle. The distribution of net earnings should not be lower than 50% of the current profit before tax. Cash dividends to stockholders should not be lower than 10% of the total dividends.

(Continued)

SCI PHARMTECH, INC. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

(iii) Earnings distribution

Based on the resolution of Board of Director held on March 12, 2024, the appropriation of earnings for the year 2023 was approved (Pending resolution of the shareholders' meeting). Moreover, based on the resolution of stockholders' meeting held on June 19, 2023, the appropriated of earnings for the year 2022 was approved. The above dividends per share were appropriated as follows:

	2023		2022	
	Amount per share (dollars)	Total amount	Amount per share (dollars)	Total amount
Dividends distributed to ordinary shareholders:				
Cash	\$ 1.25	149,386	0.25	23,846
Stock	-	-	1.25	119,228
Total		<u>\$ 149,386</u>		<u>143,074</u>

(iv) Other equity (net of tax)

	Unrealized gains (losses) from financial assets measured at fair value through other comprehensive income
Balance at January 1, 2024	\$ 25,457
Unrealized gains (losses) from financial assets measured at fair value through other comprehensive income	<u>(2,564)</u>
Balance at March 31, 2024	<u>\$ 22,893</u>
Balance at January 1, 2023	\$ (54,727)
Unrealized gains (losses) from financial assets measured at fair value through other comprehensive income	<u>(3,511)</u>
Balance at March 31, 2023	<u>\$ (58,238)</u>

(q) Share-based payment

Based on the resolution of the Board of Directors held on August 10, 2023, the Company decided to conduct a cash capital increase, information related to the share-based payment resulting from the reserved employees' subscription,. Please refer to note 6(s) of the consolidated financial statements for the year ended December 31, 2023.

(Continued)

SCI PHARMTECH, INC. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

(r) Earnings per share

The Company's earnings per share was calculated as follows:

	For the three months ended March 31,	
	2024	2023
Basic earnings per share		
Profit attributable to ordinary shareholders of the Company	\$ <u>44,509</u>	<u>63,438</u>
Weighted-average number of ordinary shares (thousand shares)	<u>119,509</u>	<u>107,305</u>
	<u>\$ 0.37</u>	<u>0.59</u>
Diluted earnings per share		
Profit attributable to ordinary shareholders of the Company	\$ <u>44,509</u>	<u>63,438</u>
Weighted-average number of ordinary shares (thousand shares)	119,509	107,305
Effect of potentially dilutive ordinary shares:		
Effect of employee compensation	<u>282</u>	<u>258</u>
Weighted-average number of ordinary shares (thousand shares) (diluted)	<u>119,791</u>	<u>107,563</u>
	<u>\$ 0.37</u>	<u>0.59</u>

The above mentioned weighted average number of ordinary shares has been retroactively adjusted for the shares obtained as stock dividends, with August 2, 2023 as the date of capital increase.

(s) Revenue from contracts with customers

(i) Disaggregation of revenue

	For the three months ended March 31,	
	2024	2023
Primary geographical markets:		
Italy	\$ 60,174	78,383
Switzerland	45,575	23,330
Germany	34,737	61,312
Spain	28,417	14,574
Japan	24,505	10,618
Netherlands	24,250	27,025
Taiwan	21,332	13,267
United States	20,439	23,389
Australia	11,051	20,641
Others	<u>39,399</u>	<u>69,240</u>
	<u>\$ 309,879</u>	<u>341,779</u>

(Continued)

SCI PHARMTECH, INC. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

	For the three months ended		
	March 31,		
	2024	2023	
Major products:			
Active Pharmaceutical Ingredients	\$ 226,748	208,711	
Intermediates	80,567	130,830	
Specialty Chemical	<u>2,564</u>	<u>2,238</u>	
	<u>\$ 309,879</u>	<u>341,779</u>	
 (ii) Contract balances			
	March 31,	December 31,	March 31,
	2024	2023	2023
Notes and accounts receivable	\$ 253,031	307,369	254,530
Less: Loss allowance	<u>-</u>	<u>-</u>	<u>-</u>
Total	<u>\$ 253,031</u>	<u>307,369</u>	<u>254,530</u>
Contract liabilities (sales received in advance)	<u>\$ 37,118</u>	<u>38,367</u>	<u>31,450</u>

Please refer to note 6(d) for the information of accounts receivable and the impairment.

The amount of revenue recognized for the three months ended March 31, 2024 and 2023, that was included in the contract liability balance at the beginning of the period was \$1,249 and \$323, respectively.

The changes of contract liabilities are arising from the difference of time point, which the Group transfers the ownership of goods and which customers do the payment.

(t) Remuneration to employees and directors

In accordance with the Articles of incorporation, the Company should contribute no less than 3% of the profit as employee remuneration and less than 2% as directors' remuneration when there is profit for the year. However, if the Company has accumulated deficits, the profit should be reserved to offset the deficit. The aforementioned employees' compensation will be distributed in shares or cash. The recipients may include the employees of the subordinate of the Company who meet certain specific requirements.

For the three months ended March 31, 2024 and 2023, the remunerations to employees amounted to \$5,720 and \$7,622, respectively, and the remunerations to directors amounted to \$630 and \$1,250, respectively. These amounts were calculated using the Company's net income before tax without the remunerations to employees and directors for each period, multiplied by the proposed percentage which is stated under the Company's proposed Article of Incorporation. These remunerations were expensed under operating costs or expenses for each period. Shares distributed to employees as employees' remuneration are calculated based on the closing price of the Company's shares on the day before the approval by the Board of Directors.

(Continued)

SCI PHARMTECH, INC. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

For the years ended December 31, 2023 and 2022, the remunerations to employees amounted to \$24,407 and \$26,091, respectively, and the remunerations to directors amounted to \$3,936 and \$4,250, respectively. The remunerations to employees in 2022 amounting to \$22,178, are calculated with the closing market prices of ordinary shares on the day before the resolution of the board of directors to distribute the remuneration to employee on March 14, 2023, and 203 thousand shares were distributed. The remunerations above are identical to those of the actual distributions. The information is available on the Market Observation Post System website.

(u) Financial Instruments

Except for the contention mentioned below, there was no significant change in the fair value of the Group's financial instruments and degree of exposure to credit risk, liquidity risk and market risk arising from financial instruments. For the related information, please refer to note 6(x) of the consolidated financial statements for the year ended December 31, 2023.

(i) Credit risk

1) Credit risk exposure

The carrying amount of financial assets represent the maximum amount exposed to credit risk.

2) Concentration of credit risk

As of March 31, 2024, December 31 and March 31, 2023, there were three, five and five major customers, respectively, that accounted for 64%, 76% and 61%, respectively, of notes and accounts receivable. Thus, credit risk is significantly centralized. In order to minimize credit risk, the Group periodically evaluates the major clients' financial positions and the possibility of collecting notes and accounts receivables to ensure the uncollectible amount is recognized appropriately as loss allowance.

3) Receivables and debt securities

a) For credit risk exposure of notes and trade receivables, please refer to note 6(d).

b) Other financial assets at amortized cost include other receivables and time deposits. The counterparties of the time deposits held by the Group are the financial institutions with investment grade credit ratings. Therefore, the credit risk is considered to be low.

(Continued)

SCI PHARMTECH, INC. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

(ii) Liquidity Risk

The following table shows the contractual maturities of financial liabilities, including estimated interest payments:

	<u>Carrying Amount</u>	<u>Contractual cash flows</u>	<u>Within a year</u>	<u>1 ~ 2 years</u>	<u>Over 2 years</u>
March 31, 2024					
Non-derivative financial liabilities:					
Short-term borrowings	\$ 66,000	(66,179)	(66,179)	-	-
Notes and accounts payable	77,385	(77,385)	(77,385)	-	-
Lease liabilities (including current and non-current)	4,304	(4,448)	(1,960)	(924)	(1,564)
Other payables	148,669	(148,669)	(148,669)	-	-
Payables on contractors and equipment	26,550	(26,550)	(26,550)	-	-
Long-term borrowings (including current portion)	959,537	(1,001,061)	(61,345)	(449,087)	(490,629)
Guarantee deposits received	1,000	(1,000)	-	-	(1,000)
	<u>\$ 1,283,445</u>	<u>(1,325,292)</u>	<u>(382,088)</u>	<u>(450,011)</u>	<u>(493,193)</u>
December 31, 2023					
Non-derivative financial liabilities:					
Short-term borrowings	\$ 175,000	(175,404)	(175,404)	-	-
Notes and accounts payable	44,251	(44,251)	(44,251)	-	-
Lease liabilities (including current and non-current)	4,804	(4,971)	(2,026)	(1,193)	(1,752)
Other payables	169,538	(169,538)	(169,538)	-	-
Payables on contractors and equipment	68,840	(68,840)	(68,840)	-	-
Long-term borrowings	862,670	(898,412)	(32,789)	(409,607)	(456,016)
Guarantee deposits received	1,000	(1,000)	-	-	(1,000)
	<u>\$ 1,326,103</u>	<u>(1,362,416)</u>	<u>(492,848)</u>	<u>(410,800)</u>	<u>(458,768)</u>

(Continued)

SCI PHARMTECH, INC. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

	<u>Carrying Amount</u>	<u>Contractual cash flows</u>	<u>Within a year</u>	<u>1 ~ 2 years</u>	<u>Over 2 years</u>
March 31, 2023					
Non-derivative financial liabilities:					
Short-term borrowings	\$ 425,000	(426,185)	(426,185)	-	-
Notes and accounts payable	46,815	(46,815)	(46,815)	-	-
Lease liabilities (including current and non-current)	616	(621)	(490)	(131)	-
Other payables	168,863	(168,863)	(168,863)	-	-
Payables on contractors and equipment	158,637	(158,637)	(158,637)	-	-
Long-term borrowings	502,179	(527,436)	(6,699)	(6,672)	(514,065)
Guarantee deposits received	<u>1,000</u>	<u>(1,000)</u>	<u>-</u>	<u>-</u>	<u>(1,000)</u>
	<u>\$ 1,303,110</u>	<u>(1,329,557)</u>	<u>(807,689)</u>	<u>(6,803)</u>	<u>(515,065)</u>

The Group is not expecting that the cash flows included in the maturity analysis could occur significantly earlier or at significantly different amount.

(iii) Currency risk

1) Exposure to foreign currency risk

The Group's significant exposure to foreign currency risk was as follow:

Foreign currency: in thousands of dollars

	<u>March 31, 2024</u>			<u>December 31, 2023</u>			<u>March 31, 2023</u>			
	<u>Foreign currency</u>	<u>Exchange rate</u>	<u>TWD</u>	<u>Foreign currency</u>	<u>Exchange rate</u>	<u>TWD</u>	<u>Foreign currency</u>	<u>Exchange rate</u>	<u>TWD</u>	
Financial assets										
Monetary items										
USD to TWD	\$	9,535	31.95	304,643	11,322	30.655	347,076	8,625	30.4	262,200
EUR to TWD		1,448	34.26	49,608	303	33.78	10,235	1,399	32.95	46,097
Financial liabilities										
Monetary items										
USD to TWD		842	31.95	26,902	633	30.655	19,405	974	30.4	29,610

2) Sensitivity analysis

The Group's exposure to foreign currency risk arises from the translation of the foreign currency exchange gains and losses on cash and cash equivalents, accounts receivable, loans and borrowings, accounts payable, accrued expenses and other payables that are denominated in foreign currency.

(Continued)

SCI PHARMTECH, INC. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

The analysis assumes that all other variables remain constant. A strengthening (weakening) 1% of the functional currency against each foreign currency for the three months ended March 31, 2024 and 2023, would have affected the net profit before tax increased or decreased \$3,273 and \$2,787, respectively. The analysis is performed on the same basis for both periods.

3) Foreign exchange gain and loss on monetary items

The exchange gains and losses of monetary items, including realized and unrealized, are changed into functional currency, which is the Group's presentation currency. For the three months ended March 31, 2024 and 2023, the exchange gains (losses), including realized and unrealized, are \$14,040 and \$(776), respectively.

(iv) Interest rate analysis

For the details of financial assets and liabilities exposed to interest rate risk, please refer to financial risk management.

The details of financial assets and liabilities exposed to interest rate risk were as follows:

	<u>Carrying amount</u>	
	<u>March 31, 2024</u>	<u>March 31, 2023</u>
Variable rate instruments:		
Financial assets	\$ 879,080	68,243
Financial liabilities	1,029,033	930,687

The following sensitivity analysis is based on the exposure to the interest rate risk of non-derivative financial instruments on the reporting date. Regarding assets with variable interest rates, the analysis is based on the assumption that the amount of assets outstanding at the reporting date was outstanding throughout the year. The rate of change is expressed as the interest rate increases or decreases by 0.25% when reporting to management internally, which also represents the Group management's assessment of the reasonably possible interest rate change.

If the interest rate had increased or decreased by 0.25%, the Group's net profit before tax would have decreased by \$ 94 and \$539, respectively, for the three months ended March 31, 2024 and 2023, with all other variable factors remaining constant. This is mainly due to the Group's bank savings and borrowings with variable interest rates.

(Continued)

SCI PHARMTECH, INC. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

(v) Other market price risks

For the years ended March 31, 2024 and 2023, the sensitivity analyses for the changes in the securities price at the reporting date were performed using the same basis for both analysis, and assuming that the other variables were unchanged, the effects on the comprehensive income were as follows:

<u>Price of securities at the reporting date</u>	For the three months ended March 31,			
	2024		2023	
	Other comprehensive income after tax	Profit or loss before tax	Other comprehensive income after tax	Profit or loss before tax
Increasing 5%	\$ 4,713	3,920	3,161	4,870
Decreasing 5%	\$ (4,713)	(3,920)	(3,161)	(4,870)

(vi) Fair value

1) Fair value hierarchy

The fair value of financial assets at fair value through profit or loss and financial assets at fair value through other comprehensive income are measured on a recurring basis. The carrying amount and fair value of the Group's financial assets and liabilities, including the information on fair value hierarchy were as follows; however, except as described in the following paragraphs, for financial instruments not measured at fair value whose carrying amount is reasonably close to the fair value, and lease liabilities, disclosure of fair value information is not required:

	March 31, 2024				
	Book value	Fair Value			Total
		Level 1	Level 2	Level 3	
Financial assets at fair value through profit or loss					
Non-derivative financial assets mandatorily measured at fair value through profit or loss	\$ 78,399	78,399	-	-	78,399
Financial assets at fair value through other comprehensive income					
Emerging stocks	94,250	94,250	-	-	94,250
Financial assets measured at amortized cost					
Cash and cash equivalents	915,963	-	-	-	-
Notes and accounts receivable	253,031	-	-	-	-
Other receivables	243	-	-	-	-
Refunded deposits (recognized as other non-current assets)	920	-	-	-	-
Subtotal	1,170,157				
Total	\$ 1,342,806				

(Continued)

SCI PHARMTECH, INC. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

	March 31, 2024				
	Book value	Fair Value			Total
		Level 1	Level 2	Level 3	
Financial liabilities measured at amortized cost					
Short-term borrowings	\$ 66,000	-	-	-	-
Notes and accounts payable	77,385	-	-	-	-
Lease liabilities (including current and non-current)	4,304	-	-	-	-
Other payables	148,669	-	-	-	-
Payables on contractors and equipment	26,550	-	-	-	-
Long-term borrowings (including current portion)	959,537	-	-	-	-
Deposits received (recognized as other non-current liabilities)	<u>1,000</u>	-	-	-	-
Total	<u>\$ 1,283,445</u>				
December 31, 2023					
	Book value	Fair Value			Total
		Level 1	Level 2	Level 3	
Financial assets at fair value through profit or loss					
Non-derivative financial assets mandatorily measured at fair value through profit or loss	\$ <u>88,998</u>	88,998	-	-	88,998
Financial assets at fair value through other comprehensive income					
Listed stocks	<u>96,814</u>	96,814	-	-	96,814
Financial assets measured at amortized cost					
Cash and cash equivalents	942,057	-	-	-	-
Notes and accounts receivable	307,369	-	-	-	-
Other receivables	151	-	-	-	-
Refunded deposits (recognized as other non-current assets)	<u>920</u>	-	-	-	-
Subtotal	<u>1,250,497</u>				
Total	<u>\$ 1,436,309</u>				

(Continued)

SCI PHARMTECH, INC. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

	December 31, 2023				
	Book value	Fair Value			Total
		Level 1	Level 2	Level 3	
Financial liabilities measured at amortized cost					
Short-term borrowings	\$ 175,000	-	-	-	-
Notes and accounts payable	44,251	-	-	-	-
Lease liabilities (including current and non-current)	4,804	-	-	-	-
Other payables	169,538	-	-	-	-
Payables on contractors and equipment	68,840	-	-	-	-
Long-term borrowings (including current portion)	862,670	-	-	-	-
Deposits received (recognized as other non-current liabilities)	<u>1,000</u>	-	-	-	-
Total	<u>\$ 1,326,103</u>				
March 31, 2023					
	Book value	Fair Value			Total
		Level 1	Level 2	Level 3	
Financial assets at fair value through profit or loss					
Non-derivative financial assets mandatorily measured at fair value through profit or loss	\$ <u>97,401</u>	97,401	-	-	97,401
Financial assets at fair value through other comprehensive income					
Emerging stocks	<u>63,212</u>	-	-	63,212	63,212
Financial assets measured at amortized cost					
Cash and cash equivalents	99,605	-	-	-	-
Notes and accounts receivable	254,530	-	-	-	-
Other receivables	141	-	-	-	-
Refunded deposits (recognized as other non-current assets)	<u>810</u>	-	-	-	-
Subtotal	<u>355,086</u>				
Total	<u>\$ 515,699</u>				

(Continued)

SCI PHARMTECH, INC. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

	March 31, 2023				
	Book value	Fair Value			Total
		Level 1	Level 2	Level 3	
Financial liabilities measured at amortized cost					
Short-term borrowings	\$ 425,000	-	-	-	-
Notes and accounts payable	46,815	-	-	-	-
Lease liabilities (including current and non-current)	616	-	-	-	-
Other payables	168,863	-	-	-	-
Payables on contractors and equipment	158,637	-	-	-	-
Long-term borrowings	502,179	-	-	-	-
Deposits received (recognized as other non-current liabilities)	<u>1,000</u>	-	-	-	-
Total	<u>\$ 1,303,110</u>				

2) Valuation techniques for financial instruments not measured at fair value

The Group's valuation techniques and assumptions used for financial instruments not measured at fair value are as follows:

a) Financial assets and liabilities measured at amortized cost

If there is quoted price generated by transactions, the recent transaction price and quoted price data is used as the basis for fair value measurement. However, if no quoted prices are available, the discounted cash flows are used to estimate fair values.

3) Valuation techniques for financial instruments measured at fair value

a) Non-derivative financial instruments

Financial instruments trade in active markets is based on quoted market prices. The quoted price of a financial instrument obtained from main exchanges and on-the-run bonds from Taipei Exchange can be used as a base to determine the fair value of the listed companies' equity instrument and debt instrument of the quoted price in an active market.

If a quoted price of a financial instrument can be obtained in time and often from exchanges, brokers, underwriters, industrial union, pricing institute, or authorities and such price can reflect those actual trading and frequently happen in the market, then the financial instrument is considered to have a quoted price in an active market. If a financial instrument is not in accord with the definition mentioned above, then it is considered to be without a quoted price in an active market. In general, market with low trading volume or high bid-ask spreads is an indication of a non-active market.

(Continued)

SCI PHARMTECH, INC. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

Measurements of fair value of financial instruments without an active market are based on a valuation technique or quoted price from a competitor. Fair value measured by a valuation technique can be extrapolated from similar financial instruments, the discounted cash flow method, or other valuation technique including a model using observable market data at the reporting date.

The measurement of fair value of a non-active market financial instruments held by the Group which do not have quoted market prices are based on the comparable market approach, with the use of price-book ratio multiple or earnings multiple of comparable companies as its basic measurement. These assumptions have been adjusted for the effect of discount without the marketability of the equity securities.

4) Transfers between Levels

For the three months ended March 31, 2024 and 2023, the Group has no any transfer between fair value.

Furthermore, the degree of the stock trading activity of Energenesis, an emerging company, and Sunny Pharmtech Inc., please refer to note 6(x) of the consolidated financial statements for the year ended December 31, 2023.

5) Reconciliation of Level 3 fair values

For the three months end March 31, 2024, the Group has no financial assets and liabilities of Level 3 fair values.

	Fair value through other comprehensive income
	Unquoted equity instruments
January 1, 2023	\$ 66,723
Total gains and losses recognized:	
In profit or loss	-
In other comprehensive income	(3,511)
March 31, 2023	\$ 63,212

(Continued)

SCI PHARMTECH, INC. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

For the three months ended March 31, 2023, total gains and losses that were included in unrealized gains and losses from financial assets at fair value through other comprehensive income were as follows:

	For the three months ended March 31, 2023
Total gains and losses recognized:	
In other comprehensive income, and presented in “unrealized gains and losses from financial assets at fair value through other comprehensive income”	\$ (3,511)
6) Quantified information on significant unobservable inputs (Level 3) used in fair value measurement	

The Group’s financial instruments that use Level 3 inputs to measure fair value include “financial assets measured at fair value through other comprehensive income – equity investments”. Financial assets at fair value through other comprehensive income – equity investments without an active market have more than one significant unobservable inputs. The significant unobservable inputs of financial assets at fair value through other comprehensive income – equity investments without an active market are individually independent, and there is no correlation between them.

Quantified information of significant unobservable inputs was as follows:

Item	Valuation technique	Significant unobservable inputs	Inter-relationship between significant unobservable inputs and fair value measurement
Fair value through other comprehensive income – equity investments without an active market	Price-Book ratio method	· The multiplier of Price-Book Ratio (As of March 31, 2023 was 1.46~2.84)	The higher the fair value is, the higher the fair value will be.
//	//	· Lack-of-Marketability discount rate (As of March 31, 2023 was 23%)	The higher the Lack-of-Marketability discount rate is, the lower the fair value will be.

(Continued)

SCI PHARMTECH, INC. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

- 7) Fair value measurements in Level 3 – sensitivity analysis of reasonably possible alternative assumptions

The Group's measurement on the fair value of financial instruments is deemed reasonable despite different valuation models or assumptions that may lead to various results. For fair value measurements in Level 3, changing one or more of the assumptions would have the following effects on profit or loss and other comprehensive income:

	Inputs	Move up or downs	Other comprehensive income	
			Favorable	Unfavorable
March 31, 2023				
Financial assets at fair value through other comprehensive income	Price-Book ratio multiples	5%	\$ <u>3,197</u>	<u>3,152</u>
Financial assets at fair value through other comprehensive income	Lack-of Marketability discount rate	5%	\$ <u>972</u>	<u>928</u>

The favorable and unfavorable effects represent the changes in fair value, and fair value is based on a variety of unobservable inputs calculated using a valuation technique. The analysis above only reflects the effects of changes in a single input, and it does not include the interrelationships with another input.

- (v) Financial risk management

There were no significant changes in the Group's financial risk management and policies as disclosed in note 6(y) of the consolidated financial statements for the year ended December 31, 2023.

- (w) Capital management

Management believes that the objectives, policies and processes of capital management of the Group has been applied consistently with those described in the consolidated financial statements for the year ended December 31, 2023. Also, management believes that there were no significant changes in the Group's capital management information as disclosed for the year ended December 31, 2023. Please refer to note 6(z) of the consolidated financial statements for the year ended December 31, 2023.

- (x) Investing and financing activities not affecting current cash flow

The Group's investing and financing activities which did not affect the current cash flow for the three months ended March 31, 2024 and 2023, were as follows:

- (i) For the acquisition of right-of-use assets by lease for the three months ended March 31, 2024 and 2023, please refer to note 6(h).

(Continued)

SCI PHARMTECH, INC. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

- (ii) Reconciliation of liabilities arising from financing activities for the three months ended March 31, 2024 and 2023, were as follows:

	January 1, 2024	Cash flows	Non-cash changes		March 31, 2024
			Acquisition	Others	
Short-term borrowings	\$ 175,000	(109,000)	-	-	66,000
Long-term borrowings (including current portion)	862,670	96,461	-	406	959,537
Lease liabilities	4,804	(500)	-	-	4,304
	<u>\$ 1,042,474</u>	<u>(13,039)</u>	<u>-</u>	<u>406</u>	<u>1,029,841</u>

	January 1, 2023	Cash flows	Non-cash changes		March 31, 2023
			Acquisition	Others	
Short-term borrowings	\$ 112,000	313,000	-	-	425,000
Long-term borrowings	432,356	69,920	-	(97)	502,179
Lease liabilities	1,023	(407)	-	-	616
	<u>\$ 545,379</u>	<u>382,513</u>	<u>-</u>	<u>(97)</u>	<u>927,795</u>

(7) Related-party transactions:

- (a) Names and relationship with related parties:

<u>Name of related party</u>	<u>Relationship with the Group</u>
Weichyun Wong	The chairman of the Company
Framosa Co., Ltd. (Framosa)	The associate of the Company

- (b) Significant transaction with related parties:

- (i) Lease

The Group rented out land and laboratory for related party, the details of the above lease transactions were as follows:

	Rental income (recorded as other income)		Other receivables from related parties		
	For the three months ended March 31,		March 31,	December 31,	March 31,
	2024	2023	2024	2023	2023
Associates-Framosa \$	<u>1,635</u>	<u>1,557</u>	<u>-</u>	<u>-</u>	<u>-</u>

	Guarantee deposits received (recorded as other non-current liability)		
	March 31,	December	March 31,
	2024	31, 2023	2023
Associates-Framosa	<u>\$ 1,000</u>	<u>1,000</u>	<u>1,000</u>

(Continued)

SCI PHARMTECH, INC. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

(ii) Property transactions

The Group entrusted Framosa with the construction of its wastewater treatment equipment, the total contract price is \$248,818 (before tax), as of March 31, 2024, December 31 and March 31, 2023, the amount of \$90,238, \$90,238 and 0, respectively, was recorded as construction in progress. As of March 31, 2024, the above transaction price of construction in progress has been paid.

(iii) Guarantee

	March 31, 2024	December 31, 2023	March 31, 2023
Associates-Framosa	\$ 400,000	400,000	-

Please refer to note 13(a)ii for the detail.

(iv) Others

The title deed of a certain portion of the land was registered in the name of Mr. Weichyun Wong due to certain legal requirements for the three months ended March 31, 2024 and 2023. Please refer to note 6(h).

(c) Key management personnel compensation

	For the three months ended March 31,	
	2024	2023
Salary and short-term employee benefits	\$ 5,385	5,717

(8) Pledged assets:

The carrying values of pledged assets were as follows:

Assets	Subject	March 31, 2024	December 31, 2023	March 31, 2023
Land	Pledged as collaterals	\$ 42,736	42,736	42,736
Building	"	2,242	2,315	2,729
		\$ 44,978	45,051	45,465

(Continued)

SCI PHARMTECH, INC. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

(9) Commitments and contingencies:

- (a) As of March 31, 2024, December 31 and March 31, 2023, the unused balance of the Group's outstanding standby letters of credit amounted to \$80,503, \$35,813 and \$2,432, respectively.
- (b) The significant outstanding purchase commitments for property, plant and equipment were as follows:

	March 31, 2024	December 31, 2023	March 31, 2023
Acquisitions of property, plant and equipment	\$ 695,244	614,765	526,969

(10) Losses Due to Major Disasters:

A major fire occurred on December 20, 2020, and caused damage to some of the Company's buildings, equipment, construction in progress and inventories, and spread to several nearby plants, resulting in damage to their property and interruption of their operations. In 2020, the Company derecognized damaged assets, including buildings, equipment and construction in progress and inventories and estimated the amount of fire indemnity for the nearby companies.

The Company is currently in the process of negotiating with the above-mentioned damaged companies for fire indemnity payments. For the indemnity payment, please refer to note 6(m) for the details. As of December 31, 2023, the indemnity payment had been fully completed.

The Company has already entered into related property insurance and public liability insurance contracts, and received insurance claims progressively from 2021. As of March 31, 2024, the above-mentioned insurance claims have not been settled yet. The Company expects to complete the application in 2024.

(11) Subsequent Events: None.

(12) Other:

- (a) The followings are the summary statement of current period employee benefits, depreciation and amortization expenses by function:

By function	For the three months ended March 31, 2024			For the three months ended March 31, 2023		
	Cost of sales	Operating expenses	Total	Cost of sales	Operating expenses	Total
By item						
Employee benefits						
Salary	44,071	17,524	61,595	38,619	20,725	59,344
Labor and health insurance	4,511	1,492	6,003	3,370	1,270	4,640
Pension	1,907	642	2,549	1,461	544	2,005
Remuneration of directors	-	630	630	-	1,250	1,250
Others	1,127	2,297	3,424	898	1,705	2,603
Depreciation	42,584	6,450	49,034	22,719	7,013	29,732
Amortization	1,038	1,065	2,103	1,042	1,072	2,114

(Continued)

SCI PHARMTECH, INC. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

(b) Seasonality of operations

The Group's operations were not affected by seasonality or cyclicity factors.

(13) Other disclosures:

(a) Information on significant transactions:

The following is the information on significant transactions required by the "Regulations Governing the Preparation of Financial Reports by Securities Issuers" for the Group for the three months ended March 31, 2024:

(i) Loans to other parties: None.

(ii) Guarantees and endorsements for other parties:

No.	Name of guarantor	Counter-party of guarantee and endorsement		Limitation on amount of guarantees and endorsements for a specific enterprise	Highest balance for guarantees and endorsements during the period	Balance of guarantees and endorsements as of reporting date	Actual usage amount during the period	Property pledged for guarantees and endorsements (Amount)	Ratio of accumulated amounts of guarantees and endorsements to net worth of the latest financial statements	Maximum amount for guarantees and endorsements	Parent company endorsements/ guarantees to third parties on behalf of subsidiary	Subsidiary endorsements/ guarantees to third parties on behalf of parent company	Endorsements/ guarantees to third parties on behalf of companies in Mainland China
		Name	Relationship with the Company										
0	The Company	Framosa Co., Ltd	The associate of the Company	514,189	400,000	400,000	78,749	-	7.78 %	2,056,759	N	N	N

Note 1: The total amount of endorsements and guarantees provided by the Company to third parties shall not exceed 40% of the latest net worth as reported in the financial statements. The maximum limit for endorsements and guarantees provided to a single enterprise shall not exceed 10% of the Company's net worth. In addition the total amount of endorsements and guarantees provided by the Company and subsidiaries to third parties shall not exceed 40% of the latest net worth as reported in the financial statements. The maximum limit for endorsements and guarantees provided to a single enterprise shall not exceed 10% of the Company's net worth.

(iii) Securities held as of March 31, 2024 (excluding investment in subsidiaries, associates and joint ventures):

Unit: thousand shares

Name of holder	Category and name of security	Relationship with company	Account title	Ending balance				Note
				Shares/Units (thousands)	Carrying value	Percentage of ownership (%)	Fair value	
The Company	Beneficiary Certificate (UPAMC James Bond Money Market Fund)	-	Current Financial asset at fair value through profit or loss	61	1,055	-	1,055	-
"	Stock (Cathay Financial Holding Co., Ltd. Preferred Stock A)	-	"	553	33,291	-	33,291	-
"	Stock (Cathay Financial Holding Co., Ltd. Preferred Stock B)	-	"	0.023	1	-	1	-
"	Stock (CTBC Financial Holding Co., Ltd. Preferred Shares B)	-	"	484	29,137	-	29,137	-
"	Stock (Shin Kong Financial Holding Co., Ltd. Preferred Shares A)	-	"	577	14,915	-	14,915	-
"	Stock (Energenesis Biomedical Co., Ltd.)	-	Financial assets at fair value through other comprehensive income	1,603	94,250	2.10 %	94,250	-

(iv) Individual securities acquired or disposed of with accumulated amount exceeding the lower of \$300 million or 20% of the capital stock: None.

(Continued)

SCI PHARMTECH, INC. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

- (v) Acquisition of individual real estate with amount exceeding the lower of \$300 million or 20% of the capital stock:

Name of company	Name of property	Transaction date	Transaction amount	Status of payment	Counter-party	Relationship with the Company	If the counter-party is a related party, disclose the previous transfer information				References for determining price	Purpose of acquisition and current condition	Others
							Owner	Relationship with the Company	Date of transfer	Amount			
The Company	Buildings	2021.10.19	\$ 630,000	\$ 472,500	ECO Technical Services Co., Ltd.	None	Not applicable	Not applicable	Not applicable	-	Price negotiation	to expand production	

- (vi) Disposal of individual real estate with amount exceeding the lower of \$300 million or 20% of the capital stock: None.
- (vii) Related-party transactions for purchases and sales with amounts exceeding the lower of \$100 million or 20% of the capital stock: None.
- (viii) Receivables from related parties with amounts exceeding the lower of \$100 million or 20% of the capital stock: None.
- (ix) Trading in derivative instruments: None.
- (x) Business relationships and significant intercompany transactions: None.

- (b) Information on investees:

The following is the information on investees for the three months ended March 31, 2024 (excluding information on investees in Mainland China):

Unit: thousand dollars/ thousand shares

Name of investor	Name of investee	Location	Main businesses and products	Original investment amount		Ending balance			Net income (losses) of investee	Share of profits/losses of investee	Note
				March 31, 2024	December 31, 2023	Shares (thousands)	Percentage of ownership	Carrying value			
The Company	Yushan Pharmaceuticals Inc.	R.O.C.	The research and development, manufacture and sale of API	351,761	351,761	35,190	100 %	352,073	(224)	(1,218)	Note 1
The Company	Framosa Co., Ltd.	R.O.C.	Circular economy by purifying and utilizing used solvents	143,750	143,750	14,375	25 %	114,528	(7,823)	(2,287)	
Yushan Pharmaceuticals Inc.	HoneyBear Biosciences, Inc.	R.O.C.	Biotechnology services	33,000	33,000	3,300	11.54 %	26,162	(9,830)	(1,831)	

Note 1 : The transactions had been eliminated in the consolidated financial statements.

- (c) Information on investment in mainland China: None.

(Continued)

SCI PHARMTECH, INC. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

(d) Major shareholders:

Unit: shares

Shareholders' Name	Shareholding	Shares	Percentage
Mercuries & Associates Holding Ltd.		35,590,777	29.78 %
Zhan Liwei		6,738,000	5.63 %

(14) Segment information:

The Group only uses one segment to assess its performance and allocate resources. Hence, there is no need to disclose the information.